Farmas USA

El precio tiene 3 ceros por delante.

Que te parece GOOG, Ricardo?
Tiene unas cuantas patentes tb.

seeeeeeeeeer bueeeeeeeeeeeeeeenos

Bajista para todo lo que no sea un metesaca a corto plazo

http://seekingalpha.com/article/2007271-ariad-pharmaceuticals-long-term-prospects-of-the-biotech-beauty-contest

ARIA

offtopic

plug cierra contrato y hoy se va a escapar como una bestia atención aal volumen que puede ser tremendo...

ARNA

Ampliación de la cobertura de Belviq:

Arena Pharmaceuticals Reports Coverage for BELVIQ(R) (lorcaserin HCl) CIV Now Greater Than 50% of Insured Commercial Lives

-- BELVIQ Now Covered by CVS Caremark --

SAN DIEGO, Calif., Feb. 10, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported that Eisai has secured improved patient access of BELVIQ® (lorcaserin HCl) with two leading healthcare benefit companies, and that the estimated number of insured commercial lives in the United States that have coverage for BELVIQ now exceeds 50 percent.

CVS Caremark customers (employers and health plans) have broadened the coverage of BELVIQ, and eligible CVS Caremark members may have access to BELVIQ in either a preferred or non-preferred brand position depending on the design of the employer benefit or health plan. In addition, Aetna recently announced that it would offer BELVIQ as a preferred brand to eligible patients as part of its pilot program to self-insured plan sponsors nationwide. The Aetna program, which offers access to lifestyle management programs and surgical options, will also measure improvements in health outcomes, productivity and medical costs.

"Securing broad reimbursement coverage for patients is an important part of the foundation for the long-term success of BELVIQ in the United States, and Eisai has continued to demonstrate its expertise in this area," said Jack Lief, Arena's President and Chief Executive Officer. "Over 50 percent of insured commercial lives with coverage for BELVIQ represents a significant increase from the approximately 30 percent of insured commercial lives that were estimated to have coverage at launch in June 2013."

Lonnel Coats, President and Chief Executive Officer of Eisai Inc., added, "We are committed to ensuring that patients have access to BELVIQ. Given how many people are struggling with their weight, it's important to provide treatment options to those who have not been able to sustain long-term weight loss with diet and exercise alone."

A patient's individual coverage for BELVIQ will vary, and may depend on the design of the patient's employer benefit or health plan. The estimated number of insured commercial lives is derived from Fingertip Formulary data, which is generally based on enrollment reported by health plans and pharmacy benefit managers.

ACHN

Conferencias para presentar Visión Corporativa.

NEW HAVEN, Conn., Feb. 10, 2014 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at two upcoming investor conferences:

Leerink Global Healthcare Conference on Thursday, February 13, 2014 at 8:55 a.m. ET at the Waldorf Astoria Hotel in New York, NY; and

Cowen and Company 34th Annual Health Care Conference on Monday, March 3, 2014 at 1:30 p.m. ET at The Boston Marriott Copley Place in Boston, MA.

ACHN

En Qfolio me aparece el precio de BAXS a 10'80. Me he puesto muy nervioso pero no veo noticias de nada y es imposible alguien puede quitarme esta presión?

Mast Therapeutics Inc(NYSEMKT:MSTX)
0.848 0.000 (0.00%)
Pre-market: 0.890 +0.042 (4.95%)
Aires is developing therapies to treat pulmonary vascular disorders such as pulmonary arterial hypertension and pulmonary hypertension due to heart failure.
MAST THERAPEUTICS SIGNS DEFINITIVE AGREEMENT TO ACQUIRE AIRES PHARMACEUTICALS, INC.
http://www.masttherapeutics.com/investors/news/
http://www.masttherapeutics.com/investors/secfilings/
http://seekingalpha.com/news/1558421-mast-therapeutics-to-buy-blood-pressure-firm-aires?source=email_rt_mc_readmore&app=1
--->>
Aires' lead product, AIR001, has orphan-drug status in the U.S. and Europe for pulmonary arterial hypertension.